SCHEMBL5240987

SCHEMBL5240987

CCOC(=O)c1c(-c2ccc(OC)cc2)c2cc(Cl)ccc2c(=O)n1C

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GABRA2 P47869 1/20 0.48
GABRB2 P47870 1/20 0.48
MAPK8 P45983 5/20 0.45
POLB P06746 1/20 0.45
GAA P10253 1/20 0.45
DPP4 P27487 2/20 0.44
TACR1 P25103 1/20 0.44
KMT2A Q03164 1/20 0.43
CYP3A4 P08684 1/20 0.43
MAP2 P11137 1/20 0.43
CSF1R P07333 1/20 0.42
ALDH1A1 P00352 2/20 0.42
KCNA5 P22460 1/20 0.42
KCNH2 Q12809 1/20 0.42
PLA2G2A P14555 1/20 0.42
CYP1A2 P05177 1/20 0.42
HPGD P15428 1/20 0.42
XBP1 P17861 1/20 0.42
CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5231074 0.89 MAPK8 (0.46) MAPK8DPP4TACR1KMT2ACSF1R
SCHEMBL5233063 0.88 TACR1 (0.46) MAPK8DPP4TACR1CSF1RALDH1A1
SCHEMBL5236738 0.85 GRIA2 (0.48) MAPK8DPP4TACR1CYP3A4MAP2
SCHEMBL5233680 0.85 TACR1 (0.55) MAPK8DPP4TACR1KMT2ACSF1R
SCHEMBL5230696 0.84 ALDH1A1 (0.55) GABRA2GABRB2MAPK8DPP4TACR1
SCHEMBL5236655 0.82 ALDH1A1 (0.46) KMT2ACYP3A4ALDH1A1CYP1A2HPGD
SCHEMBL5235496 0.80 ALDH1A1 (0.46) KMT2ACYP3A4ALDH1A1CYP1A2HPGD
SCHEMBL5239340 0.79 ALDH1A1 (0.54) GAACYP3A4ALDH1A1CYP1A2HPGD
SCHEMBL5240310 0.79 DPP4 (0.57) GABRA2GABRB2MAPK8DPP4CYP3A4
SCHEMBL6109300 0.78 MAPT (0.48) GABRA2GABRB2MAPK8DPP4TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1355886-B1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2007-07-11 EP disclosed
US-7034039-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-25 US disclosed
US-20040082607-A1 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082607-A1 Fused heterocyclic compounds DPP7, DPP4, METAP1 GABRA2 3932/4885GABRB2 2877/4885MAPK8 2612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.